Objective To evaluate the effect of the "Rapid Initiation of Antiretroviral Therapy (RAPID ART)" strategy on the initiation of treatment,virological suppression,immunological recovery,and retention rates of HIV/AIDS patients. Methods In this real-world cohort study,HIV-positive individuals firstly initiating ART at Beijing You an Hospital between April 2022 and March 2023 were divided into rapid start group (confirmed to start ART for ≤ 14 d) and non-rapid start group (confirmed to start ART for>14 d). We compared the time to start ART initiation,the virological inhibition rate at 6 and 12 months,changes in CD4+T cell counts,CD4+/CD8+ratios,and retention in care between 2 groups to ascertain the benefits of Rapid ART initiation on clinic outcomes. Results A total of 472 subjects were enrolled,including 281 (59.5％) in the rapid start group and 191 (40.5％) in the non-rapid start group. The initiation rate of ART at 3 months was 88％ in the non-rapid group and reached 95％ by 12 months. The rapid start group exhibited a significantly higher virological inhibition rate than the non-rapid start group at 6 months (90.0％ vs. 72.8％,P=0.001) and 12 months (92.5％ vs. 77.5％,P=0.001). However,there were no statistically significant differences between the groups in terms of long-term retention in care,CD4+T cell recovery,and CD4+/CD8+ratio improvement (P>0.05). Conclusions The rapid ART initiation significantly improves virological suppression rates at 6 and 12 months in HIV-infected individuals and does not significantly impact long-term rate of compliance in care or CD4 cell recovery.
维普
万方数据